Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study

In this open-label extension study of POLYP 1/2, patients with severe CRSwNP with inadequate response to nasal corticosteroids who were treated with omalizumab experienced significant improvements in endoscopic, clinical, and patient-reported outcomes over 52 weeks.

https://www.jacionline.org/article/S0091-6749(21)01364-6/abstract?rss=yes

Source: Journal of Allergy and Clinical Immunology - September 13, 2021 Category: Allergy & Immunology Authors: Philippe Gevaert, Rebecca Saenz, Jonathan Corren, Joseph K. Han, Joaquim Mullol, Stella E. Lee, Randall A. Ow, Rui Zhao, Monet Howard, Kit Wong, Lutaf Islam, Monica Ligueros-Saylan, Theodore A. Omachi, Claus Bachert Source Type: research